Últimas noticias sobre Chemed (NYSE:CHE) Bolsa

CHEMED CORP

Chemed

Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. Through its subsidiaries, the company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.

Chemed Corp

CHENGHE ACQUISITION CO L A

CHINA EASTN AIRL LTD H by China Eastern Airlines Corp. Ltd.

China Eastern Airlines Corp Ltd

CHENGHE ACQUISITION CO UNIT 1 CL A & 1/2 WT EXP

Chenghe Acquisition II Co. Class A Ordinary Shares

Chenghe Acquisition II Co

Chenghe Acquisition II Co. Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant

Chenghe Acquisition II Co. Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50

The Chefs' Warehouse, Inc. - Common Stock

The Chefs' Warehouse Inc

Check-Cap Ltd

CHAMPION ELEC METALS INC by CHAMPION ELEC METALS INC.

Champion Electric Metals Inc

Cochlear Ltd

Tranchess

CHARGING ROBOTICS INC by Charging Robotics Inc.

Charging Robotics Inc

CHEX - United States Dollar

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 15 years by 4.84% on an annualized basis producing an average annual return of 16.72%. Currently, Chemed has a market capitalization of $8.33 billion. 
Buying $100 In CHE: If an investor had bought $100 of CHE stock 15 years ago, it would be worth $1,017.09 today based on a price of $569.57 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748275213_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much $100 Invested In Chemed 15 Years Ago Would Be Worth Today

Chemed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) short percent of float has fallen 3.17% since its last report. The company recently reported that it has 231 thousand shares sold short, which is 1.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.62 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Chemed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747832435_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Chemed has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Chemed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Chemed's peer group average for short interest as a percentage of float is 9.60%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is the Market Bullish or Bearish on Chemed?

In the current market session, Chemed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) price is at $571.49, after a 2.57% spike. However, over the past month, the stock fell by 4.54%, and in the past year, by 2.35%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1747238428_0.png" alt="Past Year Chart" />

<h3>Chemed P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 55.75 in the Health Care Providers &amp; Services industry, Chemed Inc. has a lower P/E ratio of 27.17. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747238428_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

P/E Ratio Insights for Chemed

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 10 years by 5.49% on an annualized basis producing an average annual return of 16.17%. Currently, Chemed has a market capitalization of $8.36 billion. 
Buying $1000 In CHE: If an investor had bought $1000 of CHE stock 10 years ago, it would be worth $4,535.11 today based on a price of $571.49 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747233913_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Chemed Stock In The Last 10 Years

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 20 years by 6.22% on an annualized basis producing an average annual return of 14.22%. Currently, Chemed has a market capitalization of $8.40 billion. 
Buying $100 In CHE: If an investor had bought $100 of CHE stock 20 years ago, it would be worth $1,473.55 today based on a price of $574.50 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746027013_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Chemed Stock In The Last 20 Years

RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) with a Outperform and raises the price target from $667 to $674.

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Chemed, Raises Price Target to $674

WIIM

Chemed shares are trading lower. The company reported Q1 financial results.

Earnings

Earnings Beats

Chemed Q1 Adj. EPS $5.63 Beats $5.55 Estimate, Sales $646.94M Beat $641.78M Estimate

AMTB

ASGN

BANC

BPOP

BRKL

BWFG

CACI

CBAN

CHDN

CHKP

COOP

CSLR

CVLG

New Oriental Education & Technology Group

EGBN

EPRT

GATX

GLPG

GSHD

HBNC

HCSG

IMAX

INBK

KALU

KREF

LRCX

MTDR

ODFL

ORLY

OSBC

OTIS

PLXS

PTEN

SEIC

Earnings Scheduled For April 23, 2025

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 15 years by 6.62% on an annualized basis producing an average annual return of 17.1%. Currently, Chemed has a market capitalization of $8.62 billion. 
Buying $1000 In CHE: If an investor had bought $1000 of CHE stock 15 years ago, it would be worth $10,410.08 today based on a price of $588.69 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744755323_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Chemed 15 Years Ago Would Be Worth Today

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 20 years by 6.62% on an annualized basis producing an average annual return of 14.89%. Currently, Chemed has a market capitalization of $8.91 billion. 
Buying $1000 In CHE: If an investor had bought $1000 of CHE stock 20 years ago, it would be worth $15,933.32 today based on a price of $608.90 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742935513_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Chemed 20 Years Ago Would Be Worth Today

RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) with a Outperform and raises the price target from $633 to $667.

RBC Capital Maintains Outperform on Chemed, Raises Price Target to $667

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 10 years by 6.85% on an annualized basis producing an average annual return of 17.75%. Currently, Chemed has a market capitalization of $8.60 billion. 
Buying $1000 In CHE: If an investor had bought $1000 of CHE stock 10 years ago, it would be worth $5,094.50 today based on a price of $587.65 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741183213_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

Chemed shares are trading higher after the company reported better-than-expected Q4 financial results.

Chemed Q4 2024 Adj. EPS $6.83 Beats $6.78 Estimate, Sales $640M Beat $636.097M Estimate

AAOI

ABEV

ACAD

ACMR

ADTN

ALEC

AMBA

AMBC

AMSF

ARDT

ARHS

ARIS

ARKO

ASTE

ATEC

AVDX

AVNS

BATRA

BATRK

BBSI

BLMN

BXSL

BYND

CAPL

CDNA

CERT

CLDT

CLPT

COCO

COMM

CORT

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRGY

CSAN

CTRI

DHIL

DMRC

DOLE

DORM

EBAY

ECPG

EHTH

ENIC

ENOV

ERII

ESCA

ESTA

EVTC

FTAI

FWRD

GERN

GOGL

GSX Techedu Inc. American Depositary Shares

GOTU

GRBK

HCAT

HNST

IBTA

IMCR

Earnings Scheduled For February 26, 2025

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 20 years by 6.01% on an annualized basis producing an average annual return of 14.21%. Currently, Chemed has a market capitalization of $8.25 billion. 
Buying $1000 In CHE: If an investor had bought $1000 of CHE stock 20 years ago, it would be worth $14,418.12 today based on a price of $550.70 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740520816_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Chemed 20 Years Ago Would Be Worth This Much Today

AVGO

EPAM

Live On CNBC, Karen Firestone Announces Bought More EPAM Systems; Bought More Broadcom; Bought More Chemed; Announces Trimmed HealthEquity Position; Trimmed Westinghouse Air Brake Technologies Position

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 10 years by 6.46% on an annualized basis producing an average annual return of 17.78%. Currently, Chemed has a market capitalization of $8.44 billion. 
Buying $100 In CHE: If an investor had bought $100 of CHE stock 10 years ago, it would be worth $516.32 today based on a price of $563.00 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738875613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Chemed 10 Years Ago Would Be Worth This Much Today

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 20 years by 6.35% on an annualized basis producing an average annual return of 14.83%. Currently, Chemed has a market capitalization of $8.32 billion. 
Buying $1000 In CHE: If an investor had bought $1000 of CHE stock 20 years ago, it would be worth $16,306.00 today based on a price of $555.52 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737412208_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Press Releases

Chemed Corporation to Present at the 43rd Annual JPMorgan Healthcare Conference

Chemed To Report Fourth-Quarter 2024 Earnings February 26, Related Conference Call To Be Held On February 27

Chemed Corporation Declares Quarterly Dividend of 50 Cents

Chemed Reports Fourth-Quarter 2024 Results

Chemed Corporation to Present at the Oppenheimer 35th Annual Healthcare Conference

Chemed To Report First-Quarter 2025 Earnings April 23, Related Conference Call To Be Held On April 24

Chemed Reports First-Quarter 2025 Results

Chemed Corporation to Present at the Bank of America Securities Health Care Conference 2025

Chemed Corporation to Present at the 2025 RBC Global Healthcare Conference

Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Chemed

Noticias

Últimas noticias sobre Chemed (NYSE:CHE) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL